

# SCIENTIFIC REPORTS



OPEN

## Transcriptional control of intestinal cholesterol absorption, adipose energy expenditure and lipid handling by Sortilin

Sumihiko Hagita<sup>1</sup>, Maximillian A. Rogers<sup>1</sup>, Tan Pham<sup>1</sup>, Jennifer R. Wen<sup>1</sup>, Andrew K. Mlynarchik<sup>1</sup>, Masanori Aikawa<sup>1,2</sup> & Elena Aikawa<sup>1,2</sup>

The sorting receptor Sortilin functions in the regulation of glucose and lipid metabolism. Dysfunctional lipid uptake, storage, and metabolism contribute to several major human diseases including atherosclerosis and obesity. Sortilin associates with cardiovascular disease; however, the role of Sortilin in adipose tissue and lipid metabolism remains unclear. Here we show that in the low-density lipoprotein receptor-deficient (*Ldlr*<sup>-/-</sup>) atherosclerosis model, Sortilin deficiency (*Sort1*<sup>-/-</sup>) in female mice suppresses Niemann-Pick type C1-Like 1 (*Npc1l1*) mRNA levels, reduces body and white adipose tissue weight, and improves brown adipose tissue function partially via transcriptional downregulation of Krüppel-like factor 4 and Liver X receptor. Female *Ldlr*<sup>-/-</sup> *Sort1*<sup>-/-</sup> mice on a high-fat/cholesterol diet had elevated plasma Fibroblast growth factor 21 and Adiponectin, an adipokine that when reduced is associated with obesity and cardiovascular disease-related factors. Additionally, *Sort1* deficiency suppressed cholesterol absorption in both female mice *ex vivo* intestinal tissue and human colon Caco-2 cells in a similar manner to treatment with the NPC1L1 inhibitor ezetimibe. Together our findings support a novel role of Sortilin in energy regulation and lipid homeostasis in female mice, which may be a potential therapeutic target for obesity and cardiovascular disease.

Dysfunctional lipid handling and metabolism are associated with obesity and metabolic disease<sup>1,2</sup>, which in turn are major risk factors for cardiovascular disease<sup>3</sup>. Suppression of factors associated with obesity and metabolic disease may therefore reduce the development of cardiovascular disease, which has high unmet medical needs. Excess adipose tissue results in obesity. Adipose tissue is characterized as white adipose tissue (WAT), which functions as lipid storage, and brown adipose tissue (BAT) that participates in lipid metabolism and energy expenditure<sup>4–8</sup>. Further connecting cardiovascular disease to dysfunctional lipid metabolism is the intestinal cholesterol absorption-related protein, Niemann-Pick type C1-Like 1 (NPC1L1). NPC1L1 is the target of the hypercholesterolemia drug ezetimibe<sup>9</sup>. Supporting a role of intestinal cholesterol absorption in adipose tissue and cardiovascular disease, ezetimibe treatment or *Npc1l1* deficiency in mice on a high-fat diet, reduces body weight and adipogenesis<sup>9,10</sup>.

The sorting protein Sortilin functions as both a receptor and trafficking molecule with both intracellular and extracellular regulatory functions<sup>11,12</sup>. Genome wide association studies have connected the 1p13 locus harboring the Sortilin encoding gene, *SORT1* to plasma low-density lipoprotein (LDL) cholesterol, myocardial infarction, aortic aneurysm, and coronary artery calcification<sup>13–16</sup>. Sortilin has been associated with atherosclerosis, very-low density lipoprotein secretion, macrophage LDL uptake and foam cell formation, inflammatory cytokine secretion, and hepatic steatosis<sup>17–21</sup>. Additionally, we recently established a mechanistic role of Sortilin in the loading of extracellular vesicles contributing to cardiovascular calcification<sup>22</sup>, along with associating elevated serum Sortilin to aortic calcification and cardiovascular risk<sup>23</sup>.

<sup>1</sup>Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. <sup>2</sup>Center for Excellence in Vascular Biology, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. Sumihiko Hagita and Maximillian A. Rogers contributed equally to this work. Correspondence and requests for materials should be addressed to E.A. (email: [eaikawa@bwh.harvard.edu](mailto:eaikawa@bwh.harvard.edu))

While the association of Sortilin to cardiovascular disease is established, whether Sortilin plays a role in adipose tissue function, body weight gain, and factors shared by both cardiovascular disease and obesity, like NPC1L1, is unclear. Conflicting results have been reported for Sortilin in diet-induced obesity models generated by different methods. Sort1 deficiency generated by deleting 41 codons in exon 14, resulting in a reading frame disruption, reduced body weight gain and visceral fat in diet-induced obesity male C57BL/6 mice; without altering viability, fertility, or showing any gross abnormalities<sup>21</sup>. In contrast, Sort1 deficiency generated by introducing a stop codon into the second intron of the Sort1 gene altered adipose glucose metabolism but had no effect on diet-induced obesity in male C57BL/6 mice<sup>24</sup>. Given the strong connection of Sortilin to cardiovascular disease, we sought to assess if under atherosclerosis-related conditions, Sort1 deficiency alters adipose tissue function, weight gain, and NPC1L1-mediated cholesterol absorption in male and female mice.


## Results

**Sort1 deficiency reduced female Ldlr<sup>-/-</sup> mouse body and WAT weight.** As obesity and metabolic dysfunction are cardiovascular risk factors, we assessed whether Sort1 deficiency altered adipose tissue in atherosclerotic mice. Sort1-deficient mice (Sort1<sup>-/-</sup>) were generated by targeted deletion of 191 base pairs of exon 14 and crossed to C57BL/6 Ldlr-deficient mice<sup>22</sup>. To examine the effects of Sort1 deficiency on body weight, 10-week-old male and female Ldlr<sup>-/-</sup>Sort1<sup>+/+</sup> and Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice were fed either normal chow (NC) or high-fat/cholesterol (HF/HC) diet for 15 weeks. Female Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice on both NC and HF/HC diet had significantly lower body weight gain starting at three-weeks-in that was maintained through the remainder of the 15-week feeding (Fig. 1a,b). Male Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice body weight was not different from controls (Fig. 1a,b). Explaining the reduced weight gain, female Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice had lower WAT weight on both NC and HF/HC diets, compared to Ldlr<sup>-/-</sup>Sort1<sup>+/+</sup> mice (Fig. 1c). Sort1 deficiency in adipose tissue was confirmed by mRNA levels (Supplementary Fig. S1a,b) and by western blot protein abundance measurements (Fig. 1d). Food consumption, liver weight, plasma glucose, and hepatic lipid contents were not altered between Ldlr<sup>-/-</sup>Sort1<sup>+/+</sup> and Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> female mice on a 15-week HF/HC diet (Supplementary Table S1).

**Sort1 deficiency reduced WAT adipocyte size, and increased Adiponectin in HF/HC fed female Ldlr<sup>-/-</sup> mice.** Hematoxylin and eosin staining of WAT from 15-week HF/HC-fed female mice revealed smaller adipocytes in Sort1-deficient mice compared to Ldlr<sup>-/-</sup>Sort1<sup>+/+</sup> mice (Fig. 2a). Real-time PCR analysis showed white adipocyte-related genes including, Leptin and Plin1, had significantly decreased mRNA levels in female Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mouse WAT, compared to Ldlr<sup>-/-</sup>Sort1<sup>+/+</sup> mice on a 15-week HF/HC diet (Fig. 2b). Primary adipocytes differentiated from female Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mouse WAT had reduced mRNA levels of the adipose tissue-related genes Pparg, Fabp4, and Plin1 (Fig. 2c). Similar mRNA level reductions were observed in WAT from NC-fed female Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice, but not in 15-week HF/HC-diet fed male mice (Supplementary Fig. S1c,f). As adipocytes secrete Adiponectin, an adipokine that when reduced is associated with obesity and cardiovascular risk factors in animal models and humans<sup>25</sup>, we assessed Adiponectin levels in female Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice. Increased mRNA levels of the Adiponectin encoding gene, Adipoq were observed in 15-week HF/HC-fed Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mouse WAT (Fig. 2d). Plasma Adiponectin protein abundance was similarly increased in 15-week HF/HC-fed female Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice (Fig. 2e). Adipoq mRNA levels and plasma Adiponectin protein abundance was not significantly changed in NC-fed female mice, or male Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice on a 15-week HF/HC diet (Supplementary Fig. S1d,e,g,h).


**Sort1 deficiency increased BAT function in HF/HC-fed female Ldlr<sup>-/-</sup> mice.** Sort1 deficiency reduced lipid droplet size, and increased mRNA levels of Ucp1 and other brown adipose-related genes in 15-week HF/HC-diet-fed female Ldlr<sup>-/-</sup> mice BAT (Fig. 3a,b). To investigate the effects of Sort1 deficiency on BAT function, we measured the mRNA levels of genes related to inflammation and fatty acid utilization in BAT thermogenesis<sup>26-30</sup>. Female Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice on a 15-week HF/HC diet had elevated mRNA levels of Sirt3 and its regulating oxidoreductase encoding gene, Idh2 (Fig. 3c). Sort1 deficiency additionally increased Fabp3, Plin1, and Lpl mRNA levels in 15-week HF/HC-diet fed female mice; suggesting higher fatty acid utilization and lipolysis in female Ldlr<sup>-/-</sup> BAT (Fig. 3d). The  $\beta$ -oxidation gene, Cpt1b, the TCA cycle gene Acsc2, and electron transport chain genes, Atp5a1 and Cox5a, were increased by Sort1 deficiency in female Ldlr<sup>-/-</sup> BAT following a 15-week HF/HC diet (Fig. 3d); suggesting increased utilization of fatty acid for energy production in mitochondria. Similar transcriptional effects mediated by Sort1 deficiency were observed in primary adipocytes differentiated from pre-adipocytes isolated from 15-week HF/HC (Fig. 3e-g) and NC-fed female mouse BAT (Supplementary Fig. S2f-h). 15-week HF/HC fed male Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice did not exhibit improved BAT function (Supplementary Fig. S2a-c). In female Ldlr<sup>-/-</sup> mice on a 15-week HF/HC diet, Sort1 deficiency increased the mRNA levels (Fig. 3h) and plasma protein abundance (Fig. 3i) of FGF21, a growth factor involved in Adiponectin secretion and BAT function<sup>31</sup>. In 15-week HF/HC-fed male Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice, no changes were observed in Fgf21 mRNA levels or plasma protein abundance (Supplementary Fig. S2d,e). NC-fed female Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice did not have significantly increased Fgf21 levels (Supplementary Fig. S2i,j).

**Sort1 deficiency reduced intestinal Npc1l1 mRNA and cholesterol absorption.** As cholesterol absorption is associated with adipose tissue and weight gain, we assessed whether Sort1 deficiency altered Npc1l1 mRNA levels and intestinal cholesterol absorption in female Ldlr<sup>-/-</sup> mice. 15-week HF/HC diet significantly increased plasma total cholesterol (TC) and triglycerides (TG) compared to NC diet in female mice (Fig. 4a). Female Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice had reduced plasma TC on a 15-week HF/HC diet (Fig. 4a). Suggesting impaired cholesterol absorption, fecal lipid contents from individually housed female Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice had elevated TC compared to Ldlr<sup>-/-</sup>Sort1<sup>+/+</sup> mice, while fecal TG was unchanged in Sort1-deficient females on a 15-week HF/HC diet (Fig. 4b). To determine the effect of Sort1 deficiency on intestinal cholesterol absorption,



**Figure 1.** Sort1 deficiency reduced body and WAT weight in female *Ldlr<sup>-/-</sup>* mice. **(a)** Body weight in grams (g), **(b)** body weight gain, and **(c)** WAT weight ratio for *Ldlr<sup>-/-</sup>Sort1<sup>+/+</sup>* and *Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup>* mice after 15 weeks (15w) on normal chow (NC) or high-fat/cholesterol diet (HF/HC); (n = 5–10 mice/group). **(d)** Confirmation of Sortilin protein deficiency in 15-week HF/HC-diet fed female *Sort1<sup>-/-</sup>* mice WAT and brown adipose tissue (BAT); (n = 5 mice/group). GAPDH loading controls were run on the same blot, and the membrane was cut prior to incubating with primary antibody. Full-length blots are presented in Supplemental Fig. S4a and b. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001 versus sex and diet matched *Ldlr<sup>-/-</sup>Sort1<sup>+/+</sup>* mice, analyzed by t-test; values are presented as mean ± SEM.


we examined the intestinal cholesterol transporter gene, *Npc1l1* and its regulators including *Ppara*, *Ppard*, *Hnf1a*, and *Hnf4a*<sup>32–35</sup>. We also performed a fluorescent cholesterol absorption assay in jejunum of female *Ldlr<sup>-/-</sup>Sort1<sup>+/+</sup>* and *Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup>* mice. Sort1 deficiency significantly decreased *Npc1l1*, *Ppara*, *Ppard*, *Hnf1a*, and *Hnf4a* mRNA levels in female *Ldlr<sup>-/-</sup>* mice jejunum (Fig. 4c). Jejunum *Abcg5* mRNA levels were reduced,



**Figure 2.** Sort1 deficiency impaired WAT formation in female Ldlr<sup>-/-</sup> mice fed a HF/HC diet. (a) Representative hematoxylin and eosin stained sections (example of a white adipocyte outlined by dashed red line; scale bars indicate 100  $\mu\text{m}$ ), quantified adipocyte size distribution, and average size of white adipose tissue (WAT) adipocytes in female Ldlr<sup>-/-</sup>Sort1<sup>+/+</sup> and Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice fed a high-fat/cholesterol (HF/HC) diet for 15 weeks; (n = 5–6 mice/group). (b) Female mice on a HF/HC diet for 15 weeks mRNA levels of genes related to white adipocyte formation in WAT, and in (c) primary white adipocytes differentiated from female mouse WAT; (n = 3–6 mice/group). (d) WAT Adipoq mRNA levels (n = 5–6 mice/group), and (e) plasma Adiponectin protein concentration in female Ldlr<sup>-/-</sup>Sort1<sup>+/+</sup> and Ldlr<sup>-/-</sup>Sort1<sup>-/-</sup> mice fed a HF/HC diet for 15 weeks; (n = 10 mice/group). \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001 versus Ldlr<sup>-/-</sup>Sort1<sup>+/+</sup>, analyzed by t-test; values are presented as mean  $\pm$  SEM.


and Abcg8 mRNA levels were lower but did not reach significance in 15-week HF/HC-fed Sort1-deficient female mice (Fig. 4c); suggesting reduced intestinal cholesterol uptake and possibly reduced efflux in Sort1-deficient female mice. Sort1 deficiency or ezetimibe treatment reduced *ex vivo* female mice jejunum cholesterol absorption (Fig. 4d). Reduced NPC1L1 mRNA levels and cholesterol absorption were also observed in human colon Caco-2 cells with SORT1 RNA interference (Fig. 4e,f).

**Sort1 deficiency reduced WAT, BAT, and intestinal LXR-mediated transcription.** As Sort1 deficiency transcriptionally regulated WAT and BAT function, along with jejunum intestinal cholesterol absorption, we examined a key transcriptional lipid metabolism modulator, LXR $\alpha/\beta$  in female mice fed a 15-week HF/HC diet. Sort1 deficiency reduced mRNA levels of LXR $\alpha/\beta$  (Nr1h3 and Nr1h2), LXR-related genes (Rxra, Cyp51, Srebf1, Sp1), sterol synthesis and metabolism genes (Hmgcr, Hmgcs1, Cyp27a1, Ch25h), and sterol trafficking genes (Lrp1, Vldlr, Osbp) in 15-week HF/HC-fed female mice WAT (Fig. 5a and Supplementary Fig. S3a). In




**Figure 3.** Sort1 deficiency improved BAT function in female  $Ldlr^{-/-}$  mice on a HF/HC diet. **(a)** Representative hematoxylin and eosin stained sections of brown adipose tissue (BAT); magnified portions in black boxes show lipid droplets, white areas, indicated by arrows; scale bars indicate 100  $\mu\text{m}$ , and mRNA levels of **(b)** BAT-related, **(c)** anti-inflammation-related, and **(d)** energy expenditure-related genes, including fatty acid utilization,  $\beta$ -oxidation, tricarboxylic acid (TCA) cycle and electron transport chain in BAT of female  $Ldlr^{-/-}$ Sort1 $^{+/+}$  and  $Ldlr^{-/-}$ Sort1 $^{-/-}$  mice fed a high fat/high cholesterol (HF/HC) diet for 15 weeks; ( $n = 3-4$  mice/group). mRNA levels of **(e)** BAT-related, **(f)** anti-inflammation-related, and **(g)** energy expenditure-related genes in primary brown adipocytes differentiated from female mouse BAT; ( $n = 6$ ). **(h)** Fgf21 expression in BAT, and **(i)** plasma FGF21 concentration in female mice fed a HF/HC diet for 15 weeks; ( $n = 3-4$  mice/group). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$  vs.  $Ldlr^{-/-}$ Sort1 $^{+/+}$ , analyzed by t-test; values are presented as mean  $\pm$  SEM.

15-week HF/HC-fed female mice BAT, Sort1 deficiency reduced mRNA levels of LXR-related genes (Nr1h3, Nr1h2, Abca1, Abcg1, Srebf1, Ppara), and sterol metabolism and trafficking genes (Hmgcr, Hmgcs1, Ch25h, Osbp2) (Fig. 5a and Supplementary Fig. S3b). 15-week HF/HC-fed female  $Ldlr^{-/-}$ Sort1 $^{-/-}$  mouse jejunum had



**Figure 4.** Sort1 deficiency reduced *Npc111* and plasma cholesterol absorption in murine jejunum and human Caco-2 cells. (a) 15-week NC or HF/HC-fed female mice plasma total cholesterol (TC) and triglyceride (TG) levels ( $n = 8-10$  mice/group), and (b) fecal TC and TG levels in female *Ldlr*<sup>-/-</sup>*Sort1*<sup>+/+</sup> and *Ldlr*<sup>-/-</sup>*Sort1*<sup>-/-</sup> mice fed a HF/HC diet for 15 weeks ( $n = 5-6$  mice/group). (c) *Npc111*, *Npc111* regulators, and cholesterol efflux genes mRNA levels in female mouse jejunum ( $n = 6$  mice/group). (d) *ex vivo* fluorescent cholesterol absorption analysis in mouse jejunum treated with or without ezetimibe; ( $n = 6-7$  mice/group). (e) mRNA levels of *NPC1L1* and *NPC1L1* regulators ( $n = 6$ ), and (f) cholesterol absorption in Caco-2 cells with *SORT1* RNA interference (siSORT1) or scrambled control (Scr), with or without ezetimibe treatment; ( $n = 3$ ). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$  versus *Ldlr*<sup>-/-</sup>*Sort1*<sup>+/+</sup> or Scr; analyzed by t-test, except the TC and TG data in panel 4a that were analyzed by ANOVA with Tukey's multiple comparisons test, and cholesterol absorption data in panels 4d and 4f that were analyzed by ANOVA with Dunnett's multiple comparisons test; values are presented as mean  $\pm$  SEM.




**Figure 5.** Sort1 deficiency decreased LXR-related transcription in female *Ldlr*<sup>-/-</sup> mice on a HF/HC diet. (a) Heat maps of LXR-related, sterol synthesis-related, and sterol trafficking-related genes mRNA levels in WAT, BAT, and jejunum tissue of female mice fed a HF/HC diet for 15 weeks (P value shown for each gene; data also presented as bar graphs in Supplemental Fig. S3); (n = 5–6 mice/group). (b) *Klf4* mRNA levels in WAT, BAT, and jejunum of female mice on a HF/HC diet for 15 weeks; (n = 6 mice/group). \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, \*\*\*\**P* < 0.0001 vs. *Ldlr*<sup>-/-</sup>Sort1<sup>+/+</sup>, analyzed by t-test; values are presented as mean ± SEM.

reduced LXR-related (*Nr1h3*, *Nr1h2*, *Rxra*, *Apoe*, *Abca1*, *Abcg1*, *Srebf1*, *Ppara*, *Sp1*, *Hnf4a*) and sterol-related (*Hmgcr*, *Hmgcs1*, *Cyp27a1*, *Vldlr*) mRNA levels (Fig. 5a and Supplementary Fig. S3c). As a recent study demonstrated Krüppel-like factor 4 (*Klf4*) is a key cardiovascular LXR regulator<sup>36</sup>, we assessed *Klf4* levels in Sortilin-deficient mice. *Klf4* mRNA levels were significantly reduced in the WAT and BAT, but not jejunum in 15-week HF/HC-fed *Ldlr*<sup>-/-</sup>Sort1<sup>-/-</sup> mice compared to *Ldlr*<sup>-/-</sup>Sort1<sup>+/+</sup> female mice (Fig. 5b). Further implicating Sortilin as an upstream regulator of LXR-mediated transcription in some cell types, SORT1 RNA interference inhibited LXR agonist, T0901317-mediated induction of LXR (*NR1H3*, *NR1H2*) mRNA levels in human colon Caco-2 cells (Fig. 6a,b), the human hepatocyte-like cell line, HepG2 (Fig. 6a,c), and in the human embryonic kidney cell line, Hek293 (Fig. 6a,d). SORT1 deficiency reduced *KLF4* mRNA levels in HepG2 (Fig. 6c) and Hek293 cells (Fig. 6d) like Sort1-deficient female mice WAT and BAT (Fig. 5b); however, like Sort1-deficient female mice jejunum (Fig. 5b), SORT1 deficiency did not reduce *KLF4* mRNA levels in Caco-2 cells (Fig. 6b).

## Discussion

We report the following novel findings: (1) Sort1 deficiency reduces body and WAT weight, adipocyte lipid droplet size, and increases BAT function in HF/HC-fed female *Ldlr*<sup>-/-</sup> mice, (2) Sort1 deficiency increases FGF21 and Adiponectin in HF/HC-fed female *Ldlr*<sup>-/-</sup> mice, (3) Sort1 deficiency decreases *Npc1l1* mRNA levels and cholesterol absorption in female *Ldlr*<sup>-/-</sup> mice and human Caco-2 cells, and (4) Sort1 deficiency decreases *Klf4* mRNA and LXR-mediated transcription in female *Ldlr*<sup>-/-</sup> mice and human cell lines. Based on our results we present the following working model (Fig. 7): In HF/HC-fed female *Ldlr*<sup>-/-</sup> mice, Sort1 deficiency reduces LXR-mediated transcription, possibly in part via reduction of *Klf4* mRNA levels in specific cell types, as exhibited by a lack of *Klf4* mRNA levels change in intestinal tissue and cells. Transcriptional suppression of LXR leads to elevated FGF21 in BAT. Increased FGF21 increases BAT energy expenditure and induces Adiponectin release in WAT that lowers WAT mass and body weight gain. Suppression of LXR via Sort1 deficiency reduces *Npc1l1* mRNA levels that in turn lowers cholesterol absorption. Conversely, reduced *NPC1L1* may also act to lower body weight through LXR by suppressing oxysterol production. Together these mechanistic actions lower plasma TC and body weight, and associate Sortilin as a novel regulator of cardiometabolic function in female atherogenic mice.


Sortilin has been previously associated with cardiovascular disease, and metabolic and adipose tissue functions<sup>13–16,18–23,37</sup>; however, the connection of Sortilin between atherosclerosis and obesity, including its mechanistic role has not been established. The nuclear receptor, LXR reduces atherosclerotic lesion when activated in several models, but can also induce hepatic steatosis<sup>38,39</sup>. Linking cardiovascular disease with metabolic disease, LXR regulates lipid metabolism gene expression, and mice deficient in LXR have reduced HF diet-induced adipocyte size and



**Figure 6.** SORT1 deficiency suppressed LXR-mediated transcription in human Caco-2, HepG2, and Hek293 cells. **(a)** Sortilin protein reduction confirmation in Caco-2, HepG2, and Hek293 cells following SORT1 RNA interference (siSort1) or scrambled control (Scr), with or without 24-hour  $1\ \mu\text{M}$  T0901317 (T090) LXR agonist treatment; ( $n = 3$ ; representative western blots shown). GAPDH loading controls were run on the same blot, and the membrane was cut prior to incubating with primary antibody. Full-length blots are presented in Supplemental Fig. S4c. **(b)** Caco-2, **(c)** HepG2, and **(d)** Hek293 cells SORT1, LXR $\alpha/\beta$  (NR1H3, NR1H2), and KLF4 mRNA levels following SORT1 RNA interference, with or without 24-hour  $1\ \mu\text{M}$  T090 treatment; ( $n = 3-6$ ). \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$  vs. Scr control, analyzed by ANOVA with Tukey's multiple comparisons test; values are presented as mean  $\pm$  SEM.

body weight<sup>40-42</sup>. The mechanistic reason for Sort1 deficiency regulating female but not male LXR-related transcription in 15-week HF/HC-fed *Ldlr*<sup>-/-</sup> mice remains to be elucidated; however, sex-specific regulation via LXR exists in mice. While LXR deficiency reduces body weight in both male and female mice, LXR deficiency exhibits sex-specific metabolic effects in female mice<sup>43</sup>. LXR activation reduces atherosclerosis in several mouse models, whereas LXR





**Figure 7.** Transcriptional control of intestinal cholesterol absorption, adipose energy expenditure and lipid handling by Sortilin. Sortin deficiency likely decreases body weight and plasma total cholesterol (TC) in female *Ldlr*<sup>-/-</sup> mice via a KLF4-LXR signaling axis leading to decreased NPC1L1, and increased FGF21 and Adiponectin that together regulates white adipocyte formation, energy expenditure in BAT, and intestinal cholesterol absorption. Arrows indicate directionality. Dashed arrows indicate a plausible connection between KLF4 and LXR in select tissues, and that reduced NPC1L1 may partially regulate body weight via oxysterol mediated LXR-signaling.

deficiency reduces body weight in mice; therefore, the mechanisms behind improved cardiovascular pathology and reduced body weight observed in Sortin-deficient *Ldlr*<sup>-/-</sup> mice likely involve multiple pathways. The full mechanism of how Sortin deficiency reduces LXR-mediated transcription in female mice and certain human cell lines requires further investigation beyond the scope of the present study; however, we identified a likely mechanistic link with Sortin deficiency reducing the LXR-regulator, *Klf4* *in vitro* and *in vivo* in examined cell types.

Connected to WAT regulation, our results support the involvement of increased energy expenditure in the suppression of female *Ldlr*<sup>-/-</sup>Sortin<sup>-/-</sup> weight gain via improved BAT function. In agreement with our finding of reduced LXR-mediated transcription and increased BAT function in HF/HF-fed female *Ldlr*<sup>-/-</sup>Sortin<sup>-/-</sup> mice adipose tissue, LXR induction decreases BAT function<sup>42,44-46</sup>. BAT regulation of energy expenditure and obesity involves several genes that had increased mRNA levels in female *Ldlr*<sup>-/-</sup>Sortin<sup>-/-</sup> mice, including *Ucp1*, *Dio2*, *Prdm16*, and *Bmp8b*<sup>45-50</sup>. BAT can also act as a secretory tissue, including secreting FGF21. FGF21 acts on lipid metabolism and weight, is negatively regulated by LXR, and induces secretion of the obesity-associated adipokine, Adiponectin<sup>27,31,51</sup>.

Further tying cardiovascular pathology to energy expenditure and metabolism, we found reduced plasma TC, *Npc1l1* mRNA levels, and cholesterol absorption in Sortin-deficient female *Ldlr*<sup>-/-</sup> mice and human Caco-2 cells. In agreement with our findings, *Npc1l1* deficiency or ezetimibe treatment likely protects against diet-induced obesity in mice via increased energy expenditure<sup>52</sup>. LXR signaling regulates the expression of lipid absorption and efflux genes (*Npc1l1* and *Abc*-gene family members)<sup>32</sup>. LXR agonists increase intestinal cholesterol absorption via *Npc1l1* induction<sup>53</sup>. On the other hand, the NPC1L1 inhibitor, ezetimibe, attenuates LXR signaling pathways via reduced cholesterol absorption and oxysterol production<sup>54,55</sup>. Together these studies support the notion that NPC1L1 can both regulate and be regulated by LXR. As such, it is possible that Sortin deficiency may control body weight in female atherogenic mice, at least in part via regulation of *Npc1l1* mRNA levels.

## Methods

**Mice.** Low-density lipoprotein receptor-deficient mice (*Ldlr*<sup>e/e</sup>, B6.129S7-Ldlrtm1Her/J; stock #002207) were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and crossed to Sortilin-deficient mice (Sortin<sup>-/-</sup>) generated by targeted deletion of 191 base pairs of exon 14 (genOway, Lyon, France)<sup>22</sup> to create *Ldlr*<sup>-/-</sup>Sortin<sup>+/+</sup>

and *Ldlr*<sup>-/-</sup>*Sort1*<sup>-/-</sup> mice. 10-week-old male and female littermates were fed normal chow (NC) or high-fat/high cholesterol (HF/HC) (21% fat and 1.25% cholesterol, Research Diets #D12108C, New Brunswick, NJ, USA) diet for 15 weeks. Body weight and food consumption were monitored weekly, and blood was collected from the submandibular vein prior to the start of and at 5, 10, and 15 weeks on the NC and HF/HC diets. Mice were pentobarbital euthanized after 15 weeks on the study diet, and blood, peri-gonadal white adipose tissue (WAT), intrascapular brown adipose tissue (BAT), and jejunum was collected. Plasma total cholesterol (TC), triglycerides (TG), and glucose levels were assessed using Wako Pure Chemical Industries kits (Osaka, Japan; Cholesterol E-test, Triglyceride E-test, Glucose CII-test) according to the manufacturer's protocols. Hepatic and fecal TC and TG levels were measured by chloroform:methanol (2:1) extraction in combination with the Wako TC/TG kits. Plasma Adiponectin and Fibroblast growth factor 21 levels were measured by ELISA according to the manufacturer's protocol (R&D systems, Minneapolis, MN). For histology, WAT and BAT were embedded in optimum cutting temperature compound and 7 mm serial sections were cut. Tissue samples were stained with hematoxylin and eosin (H&E). Images were captured with a digital camera (DS-Fi1c, Nikon, Melville, NY, USA) and adipocyte size was quantified using Image J software (National Institutes of Health, Bethesda, MD) as previously described<sup>56</sup>. All animal experiments were approved by and performed in compliance with the Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center (protocol #010-2016).

**Cell culture.** Isolated WAT and BAT was minced, and then incubated in digestion solution (Dulbecco's Modified Eagle's Medium (DMEM), Thermo Fisher Scientific, Waltham, MA, USA) with 5% bovine serum albumin (BSA, Sigma Aldrich, St Louis, MO, USA) and 3.3 mg/mL of Collagenase Type I (Worthington Biochemical Corp., Lakewood, NJ, USA) for 60 minutes at 37°C. The cell suspension was filtered through a 100 µm cell strainer (Corning, Corning, NY, USA) followed by centrifugation (1350 rpm for 10 min). The remaining pellet was suspended with ACK red blood cell lysing buffer (Thermo Fisher Scientific) and centrifuged again. After centrifugation, the cell pellet was re-suspended in DMEM containing 10% fetal bovine serum (FBS, Thermo Fisher Scientific), 50 µg/mL Gentamicin (Corning), 50 U/mL penicillin, and 50 g/mL streptomycin (Corning), and incubated in 5% CO<sub>2</sub> incubator. After reaching confluency, pre-adipocytes isolated from WAT were treated with adipogenic medium (DMEM containing 10% FBS, gentamicin, penicillin, streptomycin, 25 nM insulin, 1 nM Triiodo-L-thyronine (T3, Sigma Aldrich), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma Aldrich), 1 µM dexamethasone (Sigma Aldrich), 1 µM Rosiglitazone (Sigma Aldrich), 500 µM palmitic acid (Sigma Aldrich)). After two days, cells were cultured in insulin medium containing 25 nM insulin, 1 nM T3, 1 µM dexamethasone and 500 µM palmitic acid for 5 to 6 days. Primary pre-adipocytes isolated from BAT were treated with induction medium (DMEM with 10% FBS, gentamicin, penicillin, streptomycin, 200 µM Ascorbic acid (Sigma Aldrich), 25 nM insulin (Sigma Aldrich), 1 nM T3, 0.5 mM IBMX), 1 µM dexamethasone (Sigma Aldrich), 0.25 mM indomethacin (Sigma Aldrich)). After a day in induction media, cells were cultured in DMEM with 10% FBS, gentamicin, penicillin, streptomycin, 200 µM Ascorbic acid, 25 nM insulin, 1 nM T3, 0.25 mM indomethacin, 1 µM CL316243 (Thermo Fisher Scientific) for 5 to 6 days.

Caco-2, Hek293, and HepG2 cells were obtained from ATCC (Manassas, VA, USA). Caco-2 cells were cultured in DMEM with 10% FBS, 1% penicillin and streptomycin, and 1% Non-Essential Amino Acids Solution (NEAA, Thermo Fisher Scientific). Hek293 cells were cultured in DMEM with 10% FBS, 1% penicillin and streptomycin. HepG2 cells were cultured in Eagle's Minimum Essential Medium (ATCC, Manassas, VA, USA) containing 10% FBS, 1% penicillin and streptomycin. RNA silencing was performed as described previously<sup>22</sup>. Briefly, 50 nM siRNA against *Sort1* (L-010620, ONTARGETplus SMART-pool, Thermo Fisher Scientific) and non-targeting siRNA (ON-TARGET Non-Targeting Pool, Thermo Fisher Scientific) were transferred into cells using Dharmafect 4 (Thermo Fisher Scientific) or Lipofectamine RNAiMAX (Thermo Fisher Scientific) according to manufacturer's protocols. RNA interference was performed over a 72-hour period. For LXR agonist experiments, LXR agonist treatment was performed by incubating cells in the final 24 hours of the 72-hour period with 1 µM of the LXR agonist T0901317 in DMSO (synthesized and HPLC purified by Kowa Company LTD, Tokyo, Japan).

**Intestinal cholesterol absorption.** Caco-2 cells were seeded in DMEM containing 10% FBS, 1% penicillin and streptomycin, and 1% NEAA, at  $4 \times 10^5$  cells per well in a 12-well plate. Between 15 and 21 days after confluency, differentiated cells were washed with PBS twice and pre-incubated in serum-free DMEM for 16 hours. After pre-incubation, cells were washed with transportation buffer (140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl<sub>2</sub>, 0.8 mM MgSO<sub>4</sub>, 5 mM Glucose, 25 mM Tris (pH 7.5)) and incubated in DMEM with 5% lipoprotein-deficient serum (Sigma Aldrich) supplemented with ezetimibe (Selleck Chemicals, Houston, TX, USA) or dimethyl sulphoxide (DMSO, control) for 1 hour. After 1 hour, cells were incubated with lipid micelles (5 mM Taurocholate (Sigma Aldrich), 0.5 mM oleic acid (Sigma Aldrich), 0.04 mM phosphatidylcholine (Sigma Aldrich), 0.16 mM lysophosphatidylcholine (Sigma Aldrich), 0.3 mM mono-olein (Sigma Aldrich)), and 10 µM NBD-cholesterol (Thermo Fisher Scientific) for 4 hours. After incubation, cells were washed with PBS containing 5 mM taurocholate twice and lysed using 0.2 N NaOH with 1% SDS. Cell lysates were measured for fluorescence at excitation 465 nm and emission 535 nm, and values were normalized by protein concentration using bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific). For *ex vivo* cholesterol absorption assay, jejunum was harvested from *Ldlr*<sup>-/-</sup>*Sort1*<sup>+/+</sup> or *Ldlr*<sup>-/-</sup>*Sort1*<sup>-/-</sup> mice. Isolated tissues were cut to expose the surface using flat sections, and then cultured on 12-well plates with serum-free DMEM for 16 hours. After pre-incubation, tissues were washed with transfer buffer, and incubated with DMEM containing 5% lipoprotein-deficient serum with or without ezetimibe for 1 hour. Lipid micelles, including NBD-cholesterol were added to the culture medium and incubated for 4 hours. Tissues were homogenized using a bead-based homogenizer and NBD-cholesterol fluorescence was measured with fluorescent values normalized to total protein content.

**RNA and protein analysis.** Total RNA was extracted from tissue and cells using Trizol reagent (Invitrogen, Waltham, MA, USA) according to the manufacturer's instructions. cDNA was synthesized using a qScript cDNA Synthesis Kit (Quanta, Beverly, MA, USA). Quantitative real-time PCR was performed with commercially obtained Taqman probes (Thermo Fisher) on a 7900HT fast real-time PCR system (Applied Biosystems, Carlsbad, CA, USA). mRNA relative expression was determined by normalization to Gapdh using the delta-delta CT method. Cell protein was isolated and processed in a similar manner to which we have previously reported<sup>57</sup>. Briefly cells were washed with PBS and scraped from plates in RIPA buffer (Thermo Fisher Scientific) containing protease and phosphatase inhibitors. Protein content was determined by BCA assay, and 20 µg of total protein lysate was processed by SDS-PAGE and transferred onto nitrocellulose membranes using the iblot 2 apparatus (Thermo Fisher Scientific). Human cell line Sortilin was detected using an anti-Sortilin antibody (R&D Systems #AF3154) and GAPDH (Santa Cruz, #sc-47724, Dallas, TX, USA) was used as a loading control. Adipose tissue protein was isolated in RIPA buffer (Thermo Fisher Scientific) containing protease and phosphatase inhibitors, in a similar manner to which we have previously reported<sup>37</sup>. Briefly tissues were homogenized using a plastic pestle and run through a syringe prior to centrifuging at 5000 g for 5 minutes to pellet insoluble tissue. Supernatant protein content was quantified by BCA assay and 100 µg of total protein lysate was processed by SDS-PAGE. Mouse adipose Sortilin was detected with an anti-Sortilin antibody (Abcam #ab16640, Cambridge, UK) and GAPDH was used as a loading control.

**Graphing and statistical analysis.** Data are presented as mean ± SEM; n indicates the number of samples or independent experiments performed. Statistical analyses were performed using GraphPad Prism Version 5 (Prism Software, Inc., La Jolla, CA, USA). For comparison between two groups, t-test were performed using Prism. For comparison among multiple groups, one-way ANOVA followed by post hoc tests were performed using Prism. P values less than 0.05 were considered significant. Heat maps were generated by quantitative PCR obtained mRNA levels using Qlucore software (Lund, Sweden). The working model was generated using Microsoft PowerPoint and the Motifolio illustration tool kit (Ellicott City, MD).

**Data availability.** All data generated or analyzed during this study are included in this article.

## References

- Singla, P., Bardoloi, A. & Parkash, A. A. Metabolic effects of obesity: A review. *World J Diabetes*. **1**, 76–88 (2010).
- Lee, C. H., Olson, P. & Evans, R. M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. *Endocrinology*. **144**, 2201–2207 (2003).
- Sowers, J. R. Obesity as a cardiovascular risk factor. *Am J Med*. **115**, 37S–41S (2003).
- Rossi, F. *et al.* Cannabinoid receptor 2 as antiobesity target: Inflammation, fat storage, and browning modulation. *J Clin Endocrinol Metab*. **101**, 3469–3478 (2016).
- Schreiber, R. *et al.* Hypophagia and metabolic adaptations in mice with defective ATGL-mediated lipolysis cause resistance to HFD-induced obesity. *Proc Natl Acad Sci USA* **112**, 13850–13855 (2015).
- Veyrat-Durebex, C., Poher, A. L., Caillon, A., Montet, X. & Rohner-Jeanrenaud, F. Alterations in lipid metabolism and thermogenesis with emergence of brown adipocytes in white adipose tissue in diet-induced obesity-resistant Lou/C rats. *Am J Physiol Endocrinol Metab*. **300**, E1146–E1157 (2011).
- Whittle, A. J. *et al.* Soluble LR11/SorLA represses thermogenesis in adipose tissue and correlates with BMI in humans. *Nat Commun*. **6**, 8951, <https://doi.org/10.1038/ncomms9951> (2015).
- Godlewski, G. *et al.* Mice lacking GPR3 receptors display late-onset obese phenotype due to impaired thermogenic function in brown adipose tissue. *Sci Rep*. **5**, 14953, <https://doi.org/10.1038/srep14953> (2015).
- Labonté, E. D. *et al.* Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc111<sup>-/-</sup> mice. *Am J Physiol Gastrointest Liver Physiol*. **295**, G776–G783 (2008).
- Jia, L. *et al.* Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. *J Lipid Res*. **51**, 3135–3144 (2010).
- Rogers, M. L. *et al.* ProNGF mediates death of Natural Killer cells through activation of the p75NTR-Sortilin complex. *J Neuroimmunol*. **226**, 93–103 (2010).
- Nielsen, M. S. *et al.* The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein. *EMBO J*. **20**, 2180–2190 (2001).
- Musunuru, K. *et al.* From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. *Nature*. **466**, 714–719 (2010).
- Kathiresan, S. *et al.* Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat Genet*. **41**, 334–341 (2009).
- Jones, G. T. *et al.* A sequence variant associated with sortilin-1 (SORT1) on 1p13.3 is independently associated with abdominal aortic aneurysm. *Hum Mol Genet*. **22**, 2941–2947 (2013).
- O'Donnell, C. J. *et al.* Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. *Circulation*. **124**, 2855–2864 (2011).
- Kjolby, M., Nielsen, M. S. & Petersen, C. M. Sortilin, encoded by the cardiovascular risk gene SORT1, and its suggested functions in cardiovascular disease. *Curr Atheroscler Rep*. **4**, 496, <https://doi.org/10.1007/s11883-015-0496-7> (2015).
- Strong, A. *et al.* Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. *J Clin Invest*. **122**, 2807–2816 (2012).
- Patel, K. M. *et al.* Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosis. *Circ Res*. **116**, 789–796 (2015).
- Mortensen, M. B. *et al.* Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis. *J Clin Invest*. **124**, 5317–5322 (2014).
- Rabinowich, L. *et al.* Sortilin deficiency improves the metabolic phenotype and reduces hepatic steatosis of mice subjected to diet-induced obesity. *J Hepatol*. **62**, 175–181 (2015).
- Goettsch, C. *et al.* Sortilin mediates vascular calcification via its recruitment into extracellular vesicles. *J Clin Invest*. **126**, 1323–1336 (2016).
- Goettsch, C. *et al.* Serum Sortilin associates with aortic calcification and cardiovascular risk in men. *Arterioscler Thromb Vasc Biol*. **37**, 1005–1011 (2017).
- Li, J., Matye, D. J., Wang, Y. & Li, T. Sortilin 1 knockout alters basal adipose glucose metabolism but not diet-induced obesity in mice. *FEBS Lett*. **591**, 1018–1028 (2017).
- Beltowski, J. Adiponectin and resistin—new hormones of white adipose tissue. *Med Sci Monit*. **9**, RA55–RA61 (2003).

26. Someya, S. *et al.* Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. *Cell*. **143**, 802–812 (2010).
27. Villarroya, F., Cereijo, R., Villarroya, J. & Giralt, M. Brown adipose tissue as a secretory organ. *Nat Rev Endocrinol*. **13**, 26–35 (2017).
28. Vergnes, L., Chin, R., Young, S. G. & Reue, K. Heart-type fatty acid-binding protein is essential for efficient brown adipose tissue fatty acid oxidation and cold tolerance. *J Biol Chem*. **286**, 380–390 (2011).
29. Yu, J. *et al.* Lipid droplet remodeling and interaction with mitochondria in mouse brown adipose tissue during cold treatment. *Biochim Biophys Acta*. **1853**, 918–928 (2015).
30. Carmona, M. C. *et al.* Defective thermoregulation, impaired lipid metabolism, but preserved adrenergic induction of gene expression in brown fat of mice lacking C/EBPbeta. *Biochem J*. **389**, 47–56 (2005).
31. Holland, W. L. *et al.* An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. *Cell Metab*. **17**, 790–797 (2013).
32. Xia, X. *et al.* Liver X receptor  $\beta$  and peroxisome proliferator-activated receptor  $\delta$  regulate cholesterol transport in murine cholangiocytes. *Hepatology*. **56**, 2288–2296 (2012).
33. Iwayanagi, Y., Takada, T. & Suzuki, H. HNF4alpha is a crucial modulator of the cholesterol-dependent regulation of NPC1L1. *Pharm Res*. **25**, 1134–1141 (2008).
34. Pramfalk, C. *et al.* HNF1alpha and SREBP2 are important regulators of NPC1L1 in human liver. *J Lipid Res*. **51**, 1354–1362 (2010).
35. Iwayanagi, Y. *et al.* Human NPC1L1 expression is positively regulated by PPAR $\alpha$ . *Pharm Res*. **28**, 405–412 (2011).
36. Li, Z. *et al.* Krüppel-Like Factor 4 regulation of Cholesterol-25-Hydroxylase and Liver X Receptor mitigates atherosclerosis susceptibility. *Circulation*. **136**, 1315–1330 (2017).
37. Goettsch, C. *et al.* A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification. *Atherosclerosis*. **251**, 109–118 (2016).
38. Peng, D. *et al.* A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(–/–) mice. *Br J Pharmacol*. **162**, 1792–1804 (2011).
39. Grefhorst, A. *et al.* Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. *J Biol Chem*. **277**, 34182–34190 (2002).
40. Korach-André *et al.* Liver X receptors regulate de novo lipogenesis in a tissue-specific manner in C57BL/6 female mice. *Am J Physiol Endocrinol Metab*. **301**, E210–E222 (2011).
41. Korach-André, M., Archer, A., Barros, R. P., Parini, P. & Gustafsson, J. Å. Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity. *Proc Natl Acad Sci USA*. **108**, 403–408 (2011).
42. Kalaany, N. Y. *et al.* LXRs regulate the balance between fat storage and oxidation. *Cell Metab*. **1**, 231–244 (2005).
43. Gabbi, C. *et al.* Pancreatic exocrine insufficiency in LXRbeta–/– mice is associated with a reduction in aquaporin-1 expression. *Proc Natl Acad Sci USA*. **105**, 15052–15057 (2008).
44. Miao, Y. *et al.* Liver X receptor  $\beta$  controls thyroid hormone feedback in the brain and regulates browning of subcutaneous white adipose tissue. *Proc Natl Acad Sci USA*. **112**, 14006–14011 (2015).
45. Bigini, P. *et al.* Neuropathologic and biochemical changes during disease progression in liver X receptor beta–/– mice, a model of adult neuron disease. *J Neuropathol Exp Neurol*. **69**, 593–605 (2010).
46. Korach-André, M. *et al.* Separate and overlapping metabolic functions of LXRalpha and LXRbeta in C57BL/6 female mice. *Am J Physiol Endocrinol Metab*. **298**, E167–E178 (2010).
47. Kontani, Y. *et al.* UCP1 deficiency increases susceptibility to diet-induced obesity with age. *Aging Cell*. **4**, 147–155 (2005).
48. Marsili, A. *et al.* Mice with a targeted deletion of the type 2 deiodinase are insulin resistant and susceptible to diet induced obesity. *PLoS One*. **6**, e20832, <https://doi.org/10.1371/journal.pone.0020832> (2011).
49. Cohen, P. *et al.* Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. *Cell*. **156**, 304–316 (2014).
50. Whittle, A. J. *et al.* BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. *Cell*. **149**, 871–885 (2012).
51. Uebanso, T. *et al.* Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet. *J Nutr Biochem*. **23**, 785–790 (2012).
52. Jia, L., Betteres, J. L. & Yu, L. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. *Annu Rev Physiol*. **73**, 239–259 (2011).
53. Hu, X. *et al.* LXR $\beta$  activation increases intestinal cholesterol absorption, leading to an atherogenic lipoprotein profile. *J Intern Med*. **272**, 452–464 (2012).
54. Sugizaki, T. *et al.* The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice. *Endocrinology*. **155**, 2810–2819 (2014).
55. Enjoji, M. *et al.* NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. *Lipids Health Dis*. **9**, 29, <https://doi.org/10.1186/1476-511X-9-29> (2010).
56. Chen, H. C. & Farese, R. V. Jr. Determination of adipocyte size by computer image analysis. *J Lipid Res*. **43**, 986–989 (2002).
57. Rogers, M. A. *et al.* Dynamin-Related Protein 1 inhibition attenuates cardiovascular calcification in the presence of oxidative stress. *Circ Res*. **121**, 220–233 (2017).

## Acknowledgements

This work was supported by research grants from Kowa Company, Ltd. (M.A.). Elena Aikawa is supported by National Institutes of Health grants R01HL114805 and R01HL136431.

## Author Contributions

S.H., M.A.R., T.P., J.W. and A.K.M. contributed to the collection and analysis of the data. S.H., M.A.R. and E.A. wrote the manuscript. All authors contributed to revising and editing of the manuscript. S.H. and M.A.R. contributed equally to the study. E.A. and M.A. supervised the study.

## Additional Information

**Supplementary information** accompanies this paper at <https://doi.org/10.1038/s41598-018-27416-y>.

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2018